PolyPid Ltd. (PYPD) Stock Price & Analysis
PolyPid Ltd. (PYPD) closed at USD 4.9 on Thursday, October 15, 2026, up 1.45% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 4.83; the Oct 15, 2026 session ranged USD 4.66–4.97 on volume of 120,507 shares. Market capitalization is $99.53M, with a 52-week range of USD 3.1–5.73 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PYPD.md
Key facts (PYPD)
- Analysts: Buy (mean 1.75 on a 1–5 scale) (4 analysts), mean target USD 11.75 (range 8–14).
- Total return with dividends: 1Y +46.3% vs S&P 500 +18.1%; 5Y -97.8% vs S&P 500 +85.1%.
- Next earnings: 2026-11-11, EPS estimate USD 0.27, revenue estimate $15.0M.
Analysts (PYPD)
Consensus Buy (mean 1.75 on a 1–5 scale), 4 analysts; mean target USD 11.75 (low 8, high 14).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-21 | HC Wainwright & Co. | Reiterated | Buy | $13 |
Total return (dividends reinvested) (PYPD)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +46.3% | -97.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +46.5% | -53.4% |
| Volatility (annualized) | 57.7% | 93.4% |
| Max drawdown | -33.0% (Jul 2026→Jul 2026) | -99.0% (Nov 2021→Apr 2025) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 4.9 |
|---|---|
| Change | ▲ 1.45% (up) |
| Previous Close | USD 4.83 |
| Open | USD 4.7 |
| Day Range | USD 4.66 – 4.97 |
| 52-Week Range | USD 3.1 – 5.73 |
| Volume | 120,507 shares |
| Market Cap | $99.53M |
| Exchange | NCM |
Technical Analysis (PYPD)
Nexqual's technical model rates PYPD "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.83 (neutral) |
| vs SMA50 | Below (USD 5.09) |
| MACD | -0.06 (negative) |
Analyst Ratings (PYPD)
Wall Street analysts rate PYPD "Buy" based on 4 analysts, with a mean price target of USD 11.75 (range USD 8–14), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 11.75 |
| High Target | USD 14 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (PYPD)
| Next Earnings Date | 2026-11-11 |
|---|---|
| EPS Estimate | USD 0.27 |
| Revenue Estimate | $15.00M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.35 vs est -0.38 ▲ beat |
| 2026-03-31 | USD -0.35 vs est -0.43 ▲ beat |
| 2025-12-31 | USD -0.41 vs est -0.33 ▼ miss |
| 2025-09-30 | USD -0.37 vs est -0.52 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (PYPD)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -243.59% |
| Debt / Equity | 0.29 |
| Current Ratio | 1.35 |
| Total Cash | $6.56M |
| Total Debt | $1.57M |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (PYPD)
Nexqual rates PolyPid Ltd.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $7M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$29M (TTM) |
| Efficiency | Critical — ROE -244%, ROA -74.6% |
Ownership (PYPD)
| Insider Ownership | +12.34% |
|---|---|
| Institutional Ownership | +34.58% |
| Shares Outstanding | 20.31M |
| Float | 12.16M |
| Short % of Float | +0.83% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (PYPD)
PolyPid Ltd. is led by Dikla Czaczkes Akselbrad (age 52), CEO & Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| CEO & Director | Dikla Czaczkes Akselbrad (age 52) |
|---|---|
| Chief Financial Officer | Jonny Missulawin (age 38) |
| Chief Operating Officer - US | Ori Warshavsky (age 46) |
| Executive Vice President of Operations | Maria Rubin |
| Vice President of Human Resource | Rivi Lev-ari |
Major Backers & Investors (PYPD)
Notable institutional backers of PolyPid Ltd. include AIGH Capital Management LLC, Rosalind Advisors, Inc., DAFNA Capital Management, LLC, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AIGH Capital Management LLC | 7.89% |
| Rosalind Advisors, Inc. | 2.04% |
| DAFNA Capital Management, LLC | 1.09% |
| Morgan Stanley | 0.65% |
| Renaissance Technologies | 0.61% |
| Marshall Wace LLP | 0.6% |
| Adar1 Capital Management, LLC | 0.54% |
| Symmetry Peak Management LLC | 0.53% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt